Bausch & Lomb Corp Reports 10% Revenue Increase in Q4 2025

By Chris Stiles • Wednesday, February 18 11:37 • Permanent Link

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced its fourth-quarter and full-year 2025 financial results, revealing significant growth and expansion across various segments. The company reported a revenue of $1.405 billion for the fourth quarter of 2025, representing a 10% increase compared to the same period in 2024. On a constant currency basis, the revenue grew by approximately 7% year-over-year.

For the full year of 2025, Bausch + Lomb reported a revenue of $5.101 billion, marking a 6% increase from the previous year. Excluding the favorable foreign exchange impact, the revenue increased by approximately 5% on a constant currency basis compared to 2024.

The Vision Care segment saw revenue of $778 million for the fourth quarter of 2025, an 8% increase from the same period in 2024. For the full year, the segment's revenue reached $2.923 billion, representing a 7% increase. The growth was primarily driven by the contact lens business and increased demand for key consumer franchises.

The Surgical segment reported revenue of $249 million for the fourth quarter of 2025, marking an 8% increase from the previous year. For the full year, the segment's revenue reached $894 million, reflecting a 6% increase. The growth was attributed to increased demand for consumables and implantables, partially offset by a voluntary recall of certain products.

In the Pharmaceuticals segment, revenue was $378 million for the fourth quarter of 2025, a 16% increase from the same period in 2024. The full-year revenue for the segment reached $1.284 billion, marking a 6% increase. The growth was driven by increased sales of Miebo and growth in international pharmaceuticals.

Bausch + Lomb also provided guidance for the full year of 2026, with an expected revenue of $5.375 billion to $5.475 billion, representing a 5% to 7% constant currency growth. The company also projected a full-year adjusted EBITDA excluding acquired IPR&D (non-GAAP) of $1.000 billion to $1.050 billion.

Today the company's shares have moved -1.61% to a price of $17.16. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.